Uncategorized

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses

Nona Biosciences announced it has entered into a collaboration agreement with Michael S. Diamond, MD, PhD, of Washington University in St. Louis to discover viral targets for which few or no human monoclonal antibodies currently exist, such as western equine encephalitis virus, rabies and severe fever with thrombocytopenia syndrome virus.

Nona Biosciences and Washington University Join Forces to Tackle Emerging RNA Viruses Read More »

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting

Modalis Therapeutics Corporation announced that the abstract has been accepted for a presentation in the late-breaking session at the 26th Annual Meeting of The American Society of Gene & Cell Therapy, being held in Los Angeles CA on May 16-20, 2023.

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT Annual Meeting Read More »

Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China

Everest Medicines announced that it has signed a Memorandum of Understanding for a strategic partnership with a subsidiary of Shanghai Pharma, SPH Keyuan Xinhua Pharmaceutical Co., Ltd.

Everest Medicines Announces Strategic Partnership with Shanghai Pharma Subsidiary to Accelerate the Commercialization of XERAVA in Mainland China Read More »

Scroll to Top